US FDA flags dosing risks from compounded versions of Novo’s weight-loss drug By Reuters
(Reuters) - The U.S. Food and Drug Administration on Friday warned patients and doctors about dosing errors linked to combination versions of Novo Nordisk's weight-loss and diabetes drugs. The health regulator said it had received reports…
